A multicenter, randomized control trial exploring the eradication efficacy in Chinese na?ve patients with helicobacter pylori infection treated with the tailored, quadruple and concomitant therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003486

Enrollment

Unknown

Registered

2013-02-27

Start date

2013-08-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Tailored regimen:Tailored therapy

Quadruple regimen:Quadruple therapy

Concomitant regimen:Concomitant therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Consecutive patients with dyspepsia who are referred to the three study centers for upper endoscopy; (2) HP RUT positive; (3) Aged 18 to 70 years, man or woman; (4) Never received treatment for H. pylori infection.

Exclusion criteria

Exclusion criteria: (1) Taking any drug which could influence the study results such as PPI, H2-receptor blockers, bismuth salts and antibiotics in the previous 4 weeks; (2) Gastrointestinal malignancy; (3) Previous gastric and esophageal surgeries; (4) Zollinger-Ellison syndrome; (5) Severe concomitant cardiovascular, respiratory, hematological, renal, hepatic, neurological, psychiatric or endocrine diseases; (6) History of allergy to any of the drugs used in the study; (7) Pregnancy or lactation; (8) Alcohol abuse; (9) Any other clinically significant medical condition that could increase risk of side effects.

Design outcomes

Secondary

Measure	Time frame
Adverse event rate;Compliance;	—

Primary

Measure	Time frame
Eradication rate;	—

Countries

China

Contacts

Public ContactLiya Zhou

liyazhou@medmail.com.cn+86 15611908239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026